ELUXADOLINE

/static/temp/default.svg

Search structure


Trade Names	VIBERZI
Synonyms	Eluxadoline JNJ-27018966 Truberzi Viberzi
Status
Molecule Category	UNKNOWN
ATC	A07DA06
UNII	45TPJ4MBQ1
EPA CompTox	DTXSID70235589


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	QFNHIDANIVGXPE-FNZWTVRRSA-N
Smiles	COc1ccc(CN(C(=O)[C@@H](N)Cc2c(C)cc(C(N)=O)cc2C)[C@@H](C)c2ncc(-c3ccccc3)[nH]2)cc1C(=O)O
InChI	InChI=1S/C32H35N5O5/c1-18-12-23(29(34)38)13-19(2)24(18)15-26(33)31(39)37(17-21-10-11-28(42-4)25(14-21)32(40)41)20(3)30-35-16-27(36-30)22-8-6-5-7-9-22/h5-14,16,20,26H,15,17,33H2,1-4H3,(H2,34,38)(H,35,36)(H,40,41)/t20-,26-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C32H35N5O5
Molecular Weight	569.66
AlogP	4.16
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	11.0
Polar Surface Area	164.63
Molecular species	ACID
Aromatic Rings	4.0
Heavy Atoms	42.0

Bioactivity

Mechanism of Action	Action	Reference
Mu opioid receptor agonist	AGONIST	FDA


Protein: Mu opioid receptor Description: Mu-type opioid receptor Organism : Homo sapiens P35372 ENSG00000112038

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Peptide receptor (family A GPCR) Short peptide receptor (family A GPCR) Opioid receptor	1	-	-	1	-

Assay Description	Organism	Bioactivity	Reference
Binding affinity to rat delta opioid receptor	Rattus norvegicus	1.3 nM
Binding affinity to rat mu opioid receptor	Rattus norvegicus	0.9 nM
Agonist activity at mu opioid receptor expressed in CHO-hg cells by [35S]-GTPgammaS binding assay	None	1.0 nM
Antagonist activity at delta opioid receptor in hamster vas deferens tissue	Cricetinae	89.0 nM
Binding affinity to guinea pig kappa opioid receptor	Cavia porcellus	55.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	10.83 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	9.069 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.08 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.08 %

Cross References

Resources	Reference
ChEBI	85980
ChEMBL	CHEMBL2159122
DrugBank	DB09272
DrugCentral	5001
FDA SRS	45TPJ4MBQ1
Guide to Pharmacology	7691
PubChem	11250029
SureChEMBL	SCHEMBL12971682
ZINC	ZINC000014210876

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).